rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
2003-1-31
|
pubmed:abstractText |
Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics. Patients and
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0732-183X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
421-7
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12560429-Adolescent,
pubmed-meshheading:12560429-Adult,
pubmed-meshheading:12560429-Aged,
pubmed-meshheading:12560429-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12560429-Carcinoma, Hepatocellular,
pubmed-meshheading:12560429-Drug Administration Schedule,
pubmed-meshheading:12560429-Female,
pubmed-meshheading:12560429-Fluorouracil,
pubmed-meshheading:12560429-Humans,
pubmed-meshheading:12560429-Infusions, Intravenous,
pubmed-meshheading:12560429-Injections, Subcutaneous,
pubmed-meshheading:12560429-Interferon-alpha,
pubmed-meshheading:12560429-Liver Cirrhosis,
pubmed-meshheading:12560429-Liver Neoplasms,
pubmed-meshheading:12560429-Liver Transplantation,
pubmed-meshheading:12560429-Male,
pubmed-meshheading:12560429-Middle Aged,
pubmed-meshheading:12560429-Neoadjuvant Therapy,
pubmed-meshheading:12560429-Recombinant Proteins,
pubmed-meshheading:12560429-Survival Analysis
|
pubmed:year |
2003
|
pubmed:articleTitle |
Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
|
pubmed:affiliation |
Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. yzpatt@umm.edu
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|